
P05121
PAI1_HUMANSERPINE1
Plasminogen activator inhibitor 1
Homo sapiensTaxon: 9606
3D-structureAlternative splicingDirect protein sequencingGlycoproteinProtease inhibitorProteomics identificationReference proteomeSecretedSerine protease inhibitorSignal
Longueur de Séquence
402
acides aminés
Poids Moléculaire
45.1 kDa
théorique
Structures Expérimentales
29
entrées PDB
Maladies Associées
1
enregistrées
Fonction
Serine protease inhibitor. Inhibits TMPRSS7 (PubMed:15853774). Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots (PubMed:17912461, PubMed:8481516, PubMed:9207454, PubMed:21925150). As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading (PubMed:9175705). Acts as a regulator of cell migration, independently of its role as protease inhibitor (PubMed:15001579, PubMed:9168821). It is required for stimulation of keratinocyte migration during cutaneous injury repair (PubMed:18386027). It is involved in cellular and replicative senescence (PubMed:16862142). Plays a role in alveolar type 2 cells senescence in the lung (By similarity). Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis (PubMed:25808697, PubMed:27046084)
Localisation & Distribution
Spécificité Tissulaire
Expressed in endothelial cells (PubMed:2430793, PubMed:3097076). Found in plasma, platelets, and hepatoma and fibrosarcoma cells
Maladies Associées
Plasminogen activator inhibitor-1 deficiency
A hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen.
Séquence d'Acides Aminés
MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
Format FASTA · 402 acides aminés · masse 45.1 kDa
Structures Expérimentales
29 entrées PDB1A7C1B3K1C5G1DB21DVM1DVN1LJ51OC03CVM3EOX3PB13Q023Q033R4L3UT34AQH4G8O4G8R4IC05BRR5ZLZ6GWN6GWP6GWQ6I8S6ZRV7AQF7AQG9PAI
Modifications Post-Traductionnelles
- •Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-|-Met-370 bond